Literature DB >> 18798102

Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.

Eric D Hsi1.   

Abstract

Classical Hodgkin lymphoma is now recognised as a B-cell lymphoma. Improved therapy has increased cure rates dramatically; however, relapse and death still occurs in a minority of patients. Much has been learned about the biology of Hodgkin and Reed Sternberg cells and their interactions with the microenvironment, which has informed studies exploring biologic markers that may improve upon clinical prognostic models. This manuscript reviews recent advances in our understanding of the pathobiology of cHL with an emphasis on biologic prognostic markers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18798102     DOI: 10.1080/10428190802163339

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  12 in total

1.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

2.  Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma.

Authors:  D Azambuja; Y Natkunam; I Biasoli; I S Lossos; M W Anderson; J C Morais; N Spector
Journal:  Ann Oncol       Date:  2011-05-20       Impact factor: 32.976

Review 3.  Current concepts and controversies in the management of early stage Hodgkin lymphoma.

Authors:  Lauren S Maeda; Mark Lee; Ranjana H Advani
Journal:  Leuk Lymphoma       Date:  2011-04-04

Review 4.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

5.  Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.

Authors:  S Montes-Moreno
Journal:  Adv Hematol       Date:  2010-10-24

6.  Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma.

Authors:  Denize Azambuja; Izidore S Lossos; Irene Biasoli; José Carlos Morais; Luciana Britto; Adriana Scheliga; Wolmar Pulcheri; Yasodha Natkunam; Nelson Spector
Journal:  Leuk Lymphoma       Date:  2009-11

Review 7.  New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.

Authors:  Catherine Diefenbach; Christian Steidl
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

8.  Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

Authors:  Catherine S Diefenbach; Fangxin Hong; Richard F Ambinder; Jonathon B Cohen; Michael J Robertson; Kevin A David; Ranjana H Advani; Timothy S Fenske; Stefan K Barta; Neil D Palmisiano; Jakub Svoboda; David S Morgan; Reem Karmali; Elad Sharon; Howard Streicher; Brad S Kahl; Stephen M Ansell
Journal:  Lancet Haematol       Date:  2020-09       Impact factor: 18.959

9.  Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols.

Authors:  Wesley Greaves; Lianchun Xiao; Beatriz Sanchez-Espiridion; Kranthi Kunkalla; Kunal S Dave; Cynthia S Liang; Rajesh R Singh; Anas Younes; L Jeffrey Medeiros; Francisco Vega
Journal:  J Hematol Oncol       Date:  2012-08-07       Impact factor: 17.388

10.  CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.

Authors:  Magdy Bedewy; Shereen El-Maghraby; Ahmed Bedewy
Journal:  Blood Res       Date:  2013-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.